BNP Paribas Arbitrage SA Decreases Stake in Supernus Pharmaceuticals Inc. (SUPN)
BNP Paribas Arbitrage SA reduced its stake in Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) by 40.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,858 shares of the specialty pharmaceutical company’s stock after selling 4,620 shares during the period. BNP Paribas Arbitrage SA’s holdings in Supernus Pharmaceuticals were worth $170,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Macquarie Group Ltd. raised its position in shares of Supernus Pharmaceuticals by 13.3% in the second quarter. Macquarie Group Ltd. now owns 145,504 shares of the specialty pharmaceutical company’s stock valued at $2,964,000 after buying an additional 17,104 shares during the period. Mason Street Advisors LLC bought a new position in shares of Supernus Pharmaceuticals during the second quarter valued at about $138,000. Schwab Charles Investment Management Inc. raised its position in shares of Supernus Pharmaceuticals by 6.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 137,023 shares of the specialty pharmaceutical company’s stock valued at $2,792,000 after buying an additional 8,387 shares during the period. Legal & General Group Plc raised its position in shares of Supernus Pharmaceuticals by 35.9% in the second quarter. Legal & General Group Plc now owns 7,282 shares of the specialty pharmaceutical company’s stock valued at $143,000 after buying an additional 1,924 shares during the period. Finally, Fiera Capital Corp bought a new position in shares of Supernus Pharmaceuticals during the second quarter valued at about $27,544,000. Institutional investors own 94.66% of the company’s stock.
Shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) opened at 23.78 on Friday. Supernus Pharmaceuticals Inc. has a 1-year low of $9.51 and a 1-year high of $26.84. The firm has a 50-day moving average of $23.52 and a 200 day moving average of $20.05. The company has a market capitalization of $1.18 billion, a P/E ratio of 48.53 and a beta of 1.73.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.05. The firm had revenue of $50.40 million for the quarter, compared to the consensus estimate of $49.67 million. Supernus Pharmaceuticals had a net margin of 14.94% and a return on equity of 20.99%. The company’s revenue was up 43.6% on a year-over-year basis. During the same period last year, the firm earned $0.03 EPS. On average, analysts anticipate that Supernus Pharmaceuticals Inc. will post $0.68 EPS for the current year.
Several brokerages recently issued reports on SUPN. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research report on Wednesday. Jefferies Group reissued a “buy” rating and issued a $28.00 price target (up from $23.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 4th. Northland Securities downgraded shares of Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price target for the company. in a research note on Monday, July 18th. Finally, Piper Jaffray Cos. downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 price target for the company. in a research note on Monday, July 18th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Supernus Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $25.25.
In other news, CFO Gregory S. Patrick sold 2,000 shares of the firm’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $25.00, for a total transaction of $50,000.00. Following the sale, the chief financial officer now directly owns 3,616 shares in the company, valued at approximately $90,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.10% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc. (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.